Why the study?
Pulmonary carcinosarcoma is a rare primary lung malignancy with a poor prognosis, and an appropriate treatment strategy has not been developed for unresectable disease.
Does pazopanib improve tumor response in a patient with metastatic pulmonary carcinosarcoma?
Does pazopanib improve tumor response in a patient with metastatic pulmonary carcinosarcoma?
Pazopanib may be a viable therapeutic option for patients with metastatic pulmonary carcinosarcoma, demonstrating partial response in lung metastases.
Answers are grounded in this paper and cite their sources.
Case-level partial response does not support pazopanib use; leaves open prospective trials in pulmonary carcinosarcoma.
BACKGROUND: Pulmonary carcinosarcoma (PCS) is a rare primary lung malignancy and has a poor prognosis among lung tumor histological subtypes. However, an appropriate treatment strategy has not been developed for unresectable PCS. CASE PRESENTATION: A 65-year-old man who was diagnosed with PCS was treated by surgical removal of the primary lung lesion, followed by six cycles of adjuvant chemotherapy with cisplatin plus irinotecan. Following the chemotherapy, he experienced a relapse with brain metastasis, which induced the rapid onset of left leg paralysis. Radical surgical resection and stereotactic radiosurgery to the resection cavity were performed. However, meningeal dissemination and new lung metastases occurred after a year and half. To control these multiple metastatic lesions, the patient was treated with the multiple kinase inhibitor pazopanib. No change was observed in the meningeal dissemination, while the metastatic lung lesions were prominently reduced in size following treatment with pazopanib. Consequently, the patient showed a partial response to pazopanib treatment, although the dose of pazopanib was reduced by half as a result of thrombocytopenia. CONCLUSION: This is the first report of metastatic PCS showing an evident therapeutic response to tumor-targeted therapy. We suggest that pazopanib may be a therapeutic option for patients with metastatic PCS.
No takes yet. Share an insight, caveat, or question.
Tanimoto et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: